Lantidra

Lantidra is the first FDA-approved allogeneic pancreatic islet cellular therapy designed for adults with type 1 diabetes (T1D) who experience severe hypoglycemia despite rigorous diabetes management.

Created by CellTrans Inc., it introduces an innovative approach by transplanting donor islet cells into the liver to help restore insulin production.

Mechanism of Action

The infused donor islet cells (which contain insulin-producing beta cells) release insulin, thereby decreasing or potentially eliminating the requirement for external insulin.

Efficacy

In clinical trials involving 30 patients, 70% achieved insulin independence for at least one year, with some remaining free of insulin for over five years.

90% of patients no longer faced severe hypoglycemia.

Safety & Risks

Lifelong immunosuppression is necessary, which raises the risk of infections, cancer, and organ toxicity.

Risks associated with the procedure include liver damage, portal vein thrombosis, and bleeding.

https://www.lantidra.com/